Press "Enter" to skip to content

primobolan depot for sale

The maximum concentration in blood plasma after a single subcutaneous or intramuscular injection of achieved after 6-16 hours in males and approximately 20 hours later in women. Despite the fact that there is a high individual variability, sex differences in the rate of absorption of the drug after a single intramuscular injection linked, probably with a greater thickness of subcutaneous fat in women. Approximately 80% is exposed to metabolic transformations primobolan depot for sale in the kidneys. It was found that a single intramuscular or subcutaneous injection of are bioequivalent with respect to the duration of absorption and the apparent elimination half-life of approximately 33 hours. Given the recommended dosing regimens and elimination half-life, is not expected to drug accumulation.

Indications In women:


  • induction of ovulation in infertility, caused anovulation or impaired follicular maturation.
  • Preparation of follicles for puncture in controlled ovarian hyperstimulation programs (for assisted reproduction techniques).
  • maintenance of the corpus luteum phase. In boys and men:
  • hypogonadotropic hypogonadism.
  • delayed puberty, due to failure of the pituitary gonadotrophic function.
  • cryptorchidism not due to anatomical obstruction.Contraindications
  • Hypersensitivity to human gonadotropins or to any component of the formulation;
  • established or suspected tumor, sex hormone-dependent (ovarian cancer, breast cancer and cervical cancer in women and prostate cancer, breast cancer in men) Boys (optional)
  • precocious puberty, in women (optional)
  • malformation of sexual organs incompatible with pregnancy;
  • uterine fibroids incompatible with pregnancy.The caution in women primobolan depot for sale with risk factors for thrombosis (personal or family history, heavy obesity (body mass index> 30 kg / m 2 ) or thrombophilia) may be at increased risk of venous or arterial thromboembolic events during or following treatment with gonadotropins. These women need to assess the benefits of treatment in vitro fertilization (IVF) and the possible risks. It should be noted that the pregnancy itself is also accompanied by an increased risk of thrombosis. In men and boys treatment of male patients using hCG leads to increased androgen production. Therefore:


  • Patients with latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or if there is a history of these conditions) should be under strict medical supervision, since aggravation or recurrence of the disease can sometimes be the result of increased androgen production.
  • HCG should be used cautiously in prepubertal boys in the age to avoid premature epiphyseal closure or precocious puberty.You should regularly monitor the development of the skeleton.Pregnancy and lactation:
    The drug  can be used to maintain the function of the corpus luteum, but can not be used during pregnancy. Should not be used during lactation.


    Dosage and administration:

    After adding a solvent to the lyophilisate reconstituted solution Pregnil ® slowly administered intramuscularly or subcutaneously. For women:

  • Upon induction of ovulation in infertility, caused anovulation or impaired follicular maturation.
    Usually conducted one injection of the drug primobolan depot for sale at a dose of 5000 to 10000 ME to complete drug treatment of follicle stimulating hormone.
  • In preparing the follicles to puncture in controlled ovarian hyperstimulation programs.
    Generally, a single injection of drug nin a dose of 5000 to 10000 ME to complete the treatment preparations.
  • To maintain phase luteum
    may be made from two to three repeated injections of preparation at a dose of 1000 to 3000 ME each for 9 days after ovulation and embryo transfer (e.g., 3, 6 and 9 days after ovulation induction). In boys and men: If hypogonadotropic hypogonadism 1000-2000 ME drug Pregnil ® 2-3 times a week. In the case of the combination drug may infertility Pregnil ® with additional preparation containing follitropin (FSH), 2-3 times a week. The course of treatment should last at least 3 months, when can we expect any improvement in spermatogenesis. During the treatment it is necessary to suspend the testosterone replacement therapy. Once improvement attained spermatogenesis sufficiently to maintain it in some cases, use of the isolated hCG. 
  • At a delay of puberty, due to lack of gonadotrophic pituitary function 1500 ME 2-3 times a week. The course of treatment – at least 6 months.
  • If cryptorchidism is not conditioned by anatomical obstruction